FC (Fragment Crystallizable) Protein and Glyco-engineered Antibodies Market, 2030 – ResearchAndMarkets.com

BioTech 365

FC (Fragment Crystallizable) Protein and Glyco-engineered Antibodies Market, 2030 – ResearchAndMarkets.com FC (Fragment Crystallizable) Protein and Glyco-engineered Antibodies Market, 2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Fc Protein and Glyco-engineered Antibodies Market: Focus on Type of Fc Engineering and Therapeutics (3rd edition), … Continue reading → Business Wire

New ‘atlas’ charts how antibodies attack spike protein variants

Scienmag

Antibodies capable of neutralizing multiple SARS-CoV-2 strains can inform strategies for broadly protective COVID-19 booster vaccines As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions of the virus.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncotarget: A novel format for recombinant antibody-interleukin-2 fusion proteins

Scienmag

and Alessandra Villa – alessandra.villa@philogen.com Oncotarget recently published “A novel format for recombinant antibody-interleukin-2 fusion proteins […].

COVID-19 neutralising antibody tests – an integrated approach

Pharma Phorum

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. This is where antibody tests come in. Neutralising Antibodies.

Lilly taps Lycia for protein degrader tech in $1.6bn deal

Pharma Phorum

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 That’s a slightly different mechanism to some other degrader drugs that harness proteasomes – enzyme complexes found in cells – to dispose of proteins.

Oncotarget: Urine protein biomarkers of bladder cancer

Scienmag

These Oncotarget findings suggest that urine IL-1?, IL-1ra and IL-8 are useful indicators of bladder cancer.

Scientists unmask new neutralizing antibody target on SARS-CoV-2 spike protein

Scienmag

SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity Researchers have identified another potential target for neutralizing antibodies on the SARS-CoV-2 Spike protein that is masked by metabolites in the blood. As a result of this masking, the target may be inaccessible to antibodies, because they must compete with metabolite molecules to bind to […].

Hepatitis Therapeutics Markets: Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) inhibitors, Others – Global Forecast to 2027 – ResearchAndMarkets.com

BioTech 365

Hepatitis Therapeutics Markets: Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) inhibitors, Others – Global Forecast to 2027 – ResearchAndMarkets.com Hepatitis Therapeutics Markets: Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) inhibitors, Others – Global Forecast to 2027 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The … Continue reading → Business Wire

New method identifies antibody-like proteins with diagnostic and therapeutic potential for SARS-CoV-2

Scienmag

Antibody-like proteins that capture and neutralize SARS-CoV-2 Scientists have used a new high-speed, in vitro selection method to isolate 9 antibody-like proteins (ALPs) that bind to the SARS-CoV-2 virus – 4 of which also exhibited neutralizing activity – within 4 days, according to a new study.

Latest Data from Novavax COVID-19 Vaccine Trial Involving B.1.351 Variant Shared by Protein Vaccine Maker

XTalks

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 variant.

Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope

Pharma Phorum

Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. . The post Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope appeared first on.

Blood vessels produce protein that promotes metastases

The Pharma Data

Scientists from the German Cancer research facility (DKFZ) and therefore the Medical Faculty Mannheim, Heidelberg University, have now identified a replacement protein produced by blood vessels that permits tumor cells to metastatically colonize organs.

EMA starts review of GSK/Vir COVID-19 antibody

Pharma Phorum

The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which could become the fourth drug of its type cleared for early use in the EU. . The post EMA starts review of GSK/Vir COVID-19 antibody appeared first on.

Global Pharmaceuticals Market Report 2021: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines COVID-19 Impact and Recovery to 2030 – ResearchAndMarkets.com

BioTech 365

Global Pharmaceuticals Market Report 2021: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines COVID-19 Impact and Recovery to 2030 – ResearchAndMarkets.com Global Pharmaceuticals Market Report 2021: Monoclonal Antibodies (MAbS); Therapeutic Proteins; Vaccines COVID-19 Impact and Recovery to 2030 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The … Continue reading → Business Wire

Biogen abandons tau antibody for Alzheimer’s after phase 2 miss

Pharma Phorum

Biogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been canned. The post Biogen abandons tau antibody for Alzheimer’s after phase 2 miss appeared first on.

More malaria hope as antibody protects against infection

Pharma Phorum

A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH) has provided protection for people exposed to malaria parasites for up to nine months. The post More malaria hope as antibody protects against infection appeared first on.

Antibody Structure: All You Ever Wanted – and Needed – to Know

BioSpace

Simply put, an antibody is a large, Y-shaped blood protein produced by plasma cells that the immune system uses to take down pathogens like bacteria – and of course, viruses like SARS-CoV-2

Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target

Bio Pharma Dive

The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers

Ultrasensitive blood test detects viral protein, confirms vaccine activates robust immune response

Scienmag

In series of samples collected from individuals vaccinated against COVID-19, an ultrasensitive test detected low concentrations of circulating antigen; Following robust production of antibodies, viral protein declined to undetectable levels The carefully orchestrated dance between the immune system and the viral proteins that induce immunity against COVID-19 may be more complex than previously thought.

Atezolizumab: A Monoclonal Antibody that has Been Designed to Bind a Protein Called Programmed Death-ligand 1 (PD-L1) – Global Emerging Insight and Market Forecast 2021-2030 – ResearchAndMarkets.com

BioTech 365

Atezolizumab: A Monoclonal Antibody that has Been Designed to Bind a Protein Called Programmed Death-ligand 1 (PD-L1) – Global Emerging Insight and Market Forecast 2021-2030 – ResearchAndMarkets.com Atezolizumab: A Monoclonal Antibody that has Been Designed to Bind a Protein Called … Continue reading → Business Wire

COVID-19 severity affected by proportion of antibodies targeting crucial viral protein

Scienmag

COVID-19 antibodies preferentially target a different part of the virus in mild cases of COVID-19 than they do in severe cases, and wane significantly within several months of infection, according to a new study by researchers at Stanford Medicine.

EU starts rolling review of GSK’s antibody for COVID-19

Pharma Phorum

The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which could become the fourth drug of its type cleared for early use in the EU. . EMA_News starts evaluating the monoclonal antibody sotrovimab.

Eli Lilly’s Dual Antibody Bamlanivimab and Etesevimab Treatment Lowers Risk of COVID-19 Hospitalizations and Deaths

XTalks

Data from Eli Lilly and Company’s (NYSE: LLY) Phase III clinical trial evaluating its monoclonal antibody drugs bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) show that combining the two significantly reduced the risk of COVID-19 hospitalizations and death by 70 percent.

Eli Lilly’s Bamlanivimab-Etesevimab Antibody Duo Cuts COVID-19 Hospitalizations and Deaths by 87 Percent

XTalks

Eli Lilly (NASDAQ: LLY ) shared the latest results from a late-stage study which show its combination antibody COVID-19 treatment can reduce hospitalizations and deaths by an impressive 87 percent, compared with placebo. The antibody was developed in conjunction with Vancouver-based AbCellera.

Regeneron’s COVID-19 Monoclonal Antibody Treatment First to Reduce Risk of Death in Hospitalized Patients

XTalks

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. Regeneron has enlisted the help of Roche to help manufacture the antibody drug.

Nanobody approach prevents the destruction of imperfect but still perfectly functional proteins

BioTech 365

Source : Synthetic llama antibodies rescue doomed proteins inside cells — ScienceDaily Columbia researchers have created a new technology using synthetic llama antibodies to prevent specific proteins from being destroyed inside cells.

FDA Offers Advice on Potency Assays for Therapeutic Protein COVID-19 Treatments

The Pharma Data

The FDA has issued straight-to-final guidance that provides sponsors of monoclonal antibody and other therapeutic protein COVID-19 treatments with recommendations for potency assays to ensure consistent product quality.

AbbVie begins trials of COVID-19 antibody therapy

Pharma Phorum

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. The pharma will also pay tiered royalties on commercial net sales of the antibody.

Scientists identify synthetic mini-antibody to combat COVID-19

Scienmag

Credit: Rayne Zaayman-Gallant/EMBL The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2.

Designed antiviral proteins inhibit SARS-CoV-2 in the lab

Scienmag

Computer design of synthetic proteins is creating potent, stable antivirals that block infection at least as well as monoclonal antibodies Credit: Ian Haydon/UW Medicine Institute for Protein Design Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19.

A protein-based COVID-19 vaccine that mimics the shape of the virus

The Pharma Data

Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses.

Antibody binding-site conserved across COVID-19 virus variants

Scienmag

The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants Credit: Kelly Lab/Penn State A tiny protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future treatments, according to a team of Penn State researchers.

Measuring Body Fat Percentage with Amazon’s Halo app + Regeneron’s Antibody Treatment Cuts Risk of COVID-19 Deaths

XTalks

The team also talked about Regeneron’s monoclonal antibody treatment for COVID-19 that has been shown to reduce the risk of deaths by 20 percent among hospitalized COVID-19 patients in recent results from the UK RECOVERY trial.

Lilly’s antibody therapy cuts hospitalisation rates in COVID-19

Pharma Phorum

Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing its antibody treatment could help prevent hospitalisation from the disease. The post Lilly’s antibody therapy cuts hospitalisation rates in COVID-19 appeared first on.

Do Therapies for Alzheimer’s & Parkinson’s that Clear Abnormal Brain Proteins Make the Diseases W.

BioSpace

One of the common research approaches to treating brain diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) is using antibodies designed to clear the accumulated misfolded proteins implicated in the diseases. To date, these drug trials have not been particularly successful at i

Regeneron’s antibody cocktail active against coronavirus, cuts symptoms

Pharma Phorum

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. REGN-COV2 is a combination of two monoclonal antibodies and was designed to block infectivity of SARS-CoV-2 , the virus that causes COVID-19.

Novartis, Molecular Partners partner to develop a scalable COVID-19 drug

Bio Pharma Dive

The two Swiss firms will develop protein drugs that are meant to have similar effects as coronavirus antibodies, but would be easier to mass produce

The Native Antigen Company Launches Range of SARS-CoV-2 Specific Antibodies

BioTech 365

BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibody

Pharma Phorum

Just a few days after Biogen abandoned its tau-targeting Alzheimer’s disease candidate gosuranemab, Bristol-Myers Squibb has opted into a rival drug, paying $80 million for rights to Prothena’s PRX005 antibody in phase 1 testing. . BMS inherited the option on PRX005 as part of its 2019 acquisition of Celgene, which signed an agreement with Dublin-based Prothena on the antibody the prior year.

Antibodies to SARS-CoV-2 remain stable, or even increase, seven months after infection

The Pharma Data

The results, published in Nature Communications, also support the idea that pre-existing antibodies against common cold coronaviruses could protect against COVID-19. They also analysed the neutralising activity of antibodies in collaboration with researchers at the University of Barcelona.

ExeVir ready for clinic with variant-targeting llama antibody

Pharma Phorum

Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants.

FDA Offers Advice on Assays for COVID-19 Therapeutic Proteins | 2021-02-01

The Pharma Data

The FDA issued straight-to-final guidance that provides sponsors of monoclonal antibody and other therapeutic protein COVID-19 treatments with recommendations for potency assays to ensure consistent product quality. The guidance describes various potency assay methods for sponsors to consider.

EMA backs emergency use of Lilly’s COVID antibodies

Pharma Phorum

The EMA’s human medicines committee has said two Eli Lilly antibodies are effective in people with COVID-19 who are at risk of developing severe disease, clearing the way for use in EU member states. The post EMA backs emergency use of Lilly’s COVID antibodies appeared first on.